Compare GFAI & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFAI | LSTA |
|---|---|---|
| Founded | 2018 | 1980 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 15.9M |
| IPO Year | 2020 | 2000 |
| Metric | GFAI | LSTA |
|---|---|---|
| Price | $0.22 | $1.05 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 119.4K | ★ 247.0K |
| Earning Date | 09-23-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | $11.88 | N/A |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.23 | $0.98 |
| 52 Week High | $1.16 | $5.07 |
| Indicator | GFAI | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 20.64 | 32.98 |
| Support Level | N/A | $0.99 |
| Resistance Level | $0.41 | $1.28 |
| Average True Range (ATR) | 0.02 | 0.12 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 0.32 | 11.67 |
Guardforce AI Co Ltd is an integrated solution provider, specializing in security solutions, and also focuses on implementing AI and robotics solutions to improve business operational efficiency and sales and marketing processes, especially for the retail and travel industry in the Asia Pacific region. The company's operating business segments include Secured Logistics, AI & Robotics Solution Business, and Corporate and others. The majority of its revenue is generated from the Secured Logistics segment, which includes services like cash-in-transit, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions. Geographically, the company generates maximum revenue from Thailand.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.